420 Lexington Avenue
59 articles with PAVmed
Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced it has launched Lucid Test Centers in three new metropolitan areas—Denver, Salt Lake City, and Las Vegas.
PAVmed Inc., a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc., a cancer prevention medical diagnostics company announced that the companies will host a joint business update conference call on Tuesday, November 16, 2021, at 4:30 PM EDT.
Lucid Diagnostics Inc. announced the closing on October 18, 2021 of its initial public offering of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), today announced a wholly owned subsidiary of the Company has entered into a definitive membership interests purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina-based CapNostics, LLC, which manufactures EsophaCap®—a U.S. FDA 510(k)-cleared and European CE Mark certified.
PAVmed Inc. announced that on October 26, 2021, from 1 to 3 PM EDT, it will host a virtual investor event focused on its digital health subsidiary Veris Health entitled Veris Heath: Bringing Digital Health to Cancer Care.
PAVmed Inc. today announced the company’s management team will participate in the Lake Street Capital Market's Best Ideas Growth (BIG5) Conference
PAVmed Inc., a highly differentiated, multi-product, commercial-stage medical device company, provided a business update for the Company and its major subsidiary, Lucid Diagnostics Inc., and discussed preliminary financial results for the three and six months ended June 30, 2021.
PAVmed Inc., a highly differentiated, multi-product, commercial-stage medical device company, announced that the Company will host a business update conference call on Monday, August 12, 2021, at 4:30 PM EDT.
PAVmed Inc. today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 7:20 a.m. PST / 10:20 a.m. EST.
6/19/2020Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
PAVmed Inc. to Hold SECOND QUARTER FINANCIAL RESULTS AND BUSINESS UPDATE Conference Call on August 22, 2018
PAVmed Inc. announced that the Company will report second quarter financial results on or before August 14, 2018 and host a conference call on Wednesday, August 22, 2018 at 4:30 p.m. Eastern time.
Medical device veteran joins as company approaches important regulatory and commercial milestones
PAVmed has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market
PAVmed Inc. announced the closing of its oversubscribed equity subscription rights offering (the “Rights Offering”), which raised the maximum gross proceeds of $10,350,000.
Equity subscription rights offering expired at 5:00 p.m. Eastern Time on Thursday, June 7, 2018 and, as such, the rights are no longer exercisable
Each right now entitles the holder to purchase one unit at the subscription price of $1.15 per unit and each unit remains comprised of one share of the Company’s common stock and one Series Z Warrant.
Company had filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering to stockholders of record on Monday, May 21, 2018.
Conference call to be held May 30, 2018 at 4:30 p.m. Eastern time
The effective date of the exercise price reduction will be June 1, 2018.
PAVmed and Case Western Reserve University Finalize Definitive Licensing Agreement for Groundbreaking EsoCheck Technology
PAVmed subsidiary Lucid Diagnostics Inc. secures exclusive worldwide license for EsoCheck